Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function

Biochemical Pharmacology

Volumn 78, Issue 4, 2009, Pages 355-364

  Dai, Chun ling ^a   Liang, Yong ju ^a   Chen, Li ming ^a   Zhang, Xu ^a   Deng, Wen jing ^a   Su, Xiao dong ^a   Shi, Zhi ^a,b   Wu, Chung pu ^c   Ashby Jr , Charles R ^b   Akiyama, Shin ichi ^d   Ambudkar, Suresh V ^c   Chen, Zhe sheng ^b   Fu, Li wu ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b ST JOHN'S UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

ABC transporter; Chemosensitivity; FG020326; Multidrug resistance; P glycoprotein

Indexed keywords

2 [(4 METHACRYLATE)PHENYL] 4,5 BIS(4 N,N METHYLISOPROPYLAMINOPHENYL) 1H IMIDAZOLE; AZIDOPINE; CISPLATIN; DOXORUBICIN; FG 020326; FLUOROURACIL; IMIDAZOLE DERIVATIVE; MERCAPTOPURINE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 4; PACLITAXEL; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; STRUCTURE ANALYSIS; TUMOR XENOGRAFT;

ACRYLATES; ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IMIDAZOLES; KB CELLS; MICE; MICE, NUDE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; PACLITAXEL; VINCRISTINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67349215151     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.04.023     Document Type: Article

References (50)

1. O'Connor R. The pharmacology of cancer resistance. Anticancer Res 27 (2007) 1267-1272
2. Donnenberg V.S., and Donnenberg A.D. Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol 45 (2005) 872-877
3. Sparreboom A., Danesi R., Ando Y., Chan J., and Figg W.D. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Updat 6 (2003) 71-84
4. Ambudkar S.V., Kimchi-Sarfaty C., Sauna Z.E., and Gottesman M.M. P-glycoprotein: from genomics to mechanism. Oncogene 22 (2003) 7468-7485
5. Perez-Victoria J.M., Di Pietro A., Barron D., Ravelo A.G., Castanys S., and Gamarro F. Multidrug resistance phenotype mediated by the P-glycoprotein-like transporter in Leishmania: a search for reversal agents. Curr Drug Targets 3 (2002) 311-333
6. Krishna R., and Mayer L.D. Modulation of P-glycoprotein (PGP) mediated multidrug resistance (MDR) using chemosensitizers: recent advances in the design of selective MDR modulators. Curr Med Chem 1 (2001) 163-174
7. Sikic B.I., Fisher G.A., Lum B.L., Halsey J., Beketic-Oreskovic L., and Chen G. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 40 Suppl. (1997) S13-S19
8. Dai C.L., Xiong H.Y., Tang L.F., Zhang X., Liang Y.J., Zeng M.S., et al. Tetrandrine achieved plasma concentrations capable of reversing MDR in vitro and had no apparent effect on doxorubicin pharmacokinetics in mice. Cancer Chemother Pharmacol 60 (2007) 741-750
9. Chen L.M., Wu X.P., Ruan J.W., Liang Y.J., Ding Y., Shi Z., et al. Screening novel, potent multidrug-resistant modulators from imidazole derivatives. Oncol Res 14 (2004) 355-362
10. Sikic B.I. Pharmacologic approaches to reversing multidrug resistance. Semin Hematol 34 (1997) 40-47
11. Krishna R., and Mayer L.D. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 11 (2000) 265-283
12. Thomas H., and Coley H.M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10 (2003) 159-165
13. Muller H., Pajeva I.K., Globisch C., and Wiese M. Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors. Bioorg Med Chem 16 (2008) 2448-2462
14. Morschhauser F., Zinzani P.L., Burgess M., Sloots L., Bouafia F., and Dumontet C. Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma. Leuk Lymphoma 48 (2007) 708-715
15. van Zuylen L., Sparreboom A., van der Gaast A., Nooter K., Eskens F.A., Brouwer E., et al. Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933. Eur J Cancer 38 (2002) 1090-1099
16. Guns E.S., Bullock P.L., Reimer M.L., Dixon R., Bally M., and Mayer L.D. Assessment of the involvement of CYP3A in the vitro metabolism of a new modulator of MDR in cancer chemotherapy, OC144-193, by human liver microsomes. Eur J Drug Metab Pharmacokinet 26 (2001) 273-282
17. Kuppens I.E., Witteveen E.O., Jewell R.C., Radema S.A., Paul E.M., Mangum S.G., et al. A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients. Clin Cancer Res 13 (2007) 3276-3285
18. Ruan J.W., Fu L.W., Huang Z.S., Chen L.M., MA L., and Gu L.Q. Studies on synthesis of multiaryl-substituted imidazoles and reversal activity on the multidrug resistance. Chem J Chin U 25 (2004) 870-873
19. Fu L., Liang Y., Deng L., Ding Y., Chen L., Ye Y., et al. Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Chemother Pharmacol 53 (2004) 349-356
20. Fu L.W., Zhang Y.M., Liang Y.J., Yang X.P., and Pan Q.C. The multidrug resistance of tumour cells was reversed by tetrandrine in vitro and in xenografts derived from human breast adenocarcinoma MCF-7/adr cells. Eur J Cancer 38 (2002) 418-426
21. Aoki S., Chen Z.S., Higasiyama K., Setiawan A., Akiyama S., and Kobayashi M. Reversing effect of agosterol A, a spongean sterol acetate, on multidrug resistance in human carcinoma cells. Jpn J Cancer Res 92 (2001) 886-895
22. Lee K., Klein-Szanto A.J., and Kruh G.D. Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. J Natl Cancer Inst 92 (2000) 1934-1940
23. Volk E.L., Farley K.M., Wu Y., Li F., Robey R.W., and Schneider E. Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res 62 (2002) 5035-5040
24. Litman T., Brangi M., Hudson E., Fetsch P., Abati A., Ross D.D., et al. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 113 Pt 11 (2000) 2011-2021
25. Kubota T., Furukawa T., Tanino H., Suto A., Otan Y., Watanabe M., et al. Resistant mechanisms of anthracyclines-pirarubicin might partly break through the P-glycoprotein-mediated drug-resistance of human breast cancer tissues. Breast Cancer 8 (2001) 333-338
26. Slovak M.L., Ho J.P., Cole S.P., Deeley R.G., Greenberger L., de Vries E.G., et al. The LRP gene encoding a major vault protein associated with drug resistance maps proximal to MRP on chromosome 16: evidence that chromosome breakage plays a key role in MRP or LRP gene amplification. Cancer Res 55 (1995) 4214-4219
27. Shi Z., Liang Y.J., Chen Z.S., Wang X.W., Wang X.H., Ding Y., et al. Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo. Cancer Biol Ther 5 (2006) 39-47
28. Chen L.M., Liang Y.J., Ruan J.W., Ding Y., Wang X.W., Shi Z., et al. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318. J Pharm Pharmacol 56 (2004) 1061-1066
29. Dai C.L., Li S., Liang Y.J., Liao H., Deng W.J., and Yan L. Fu LW A method for determining the concentration of FG020326 in mice plasma by RP-HPLC. Chin Pharmacol Bull 23 (2007) 4
30. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72 (1976) 248-254
31. Yonemoto H., Ogino S., Nakashima M.N., Wada M., and Nakashima K. Determination of paclitaxel in human and rat blood samples after administration of low dose paclitaxel by HPLC-UV detection. Biomed Chromatogr 21 (2007) 310-317
32. Ramachandra M., Ambudkar S.V., Chen D., Hrycyna C.A., Dey S., Gottesman M.M., et al. Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state. Biochemistry 37 (1998) 5010-5019
33. Shi Z., Peng X.X., Kim I.W., Shukla S., Si Q.S., Robey R.W., et al. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res 67 (2007) 11012-11020
34. Shi Z., Liang Y.J., Chen Z.S., Wang X.H., Ding Y., Chen L.M., et al. Overexpression of Survivin and XIAP in MDR cancer cells unrelated to P-glycoprotein. Oncol Rep 17 (2007) 969-976
35. Holmes F.A., and Rowinsky E.K. Pharmacokinetic profiles of doxorubicin in combination with taxanes. Semin Oncol 28 (2001) 8-14
36. Danesi R., Conte P.F., and Del Tacca M. Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer. Clin Pharmacokinet 37 (1999) 195-211
37. Pal D., and Mitra A.K. MDR- and CYP3A4-mediated drug-drug interactions. J Neuroimmune Pharmacol 1 (2006) 323-339
38. Pal D., and Mitra A.K. MDR- and CYP3A4-mediated drug-herbal interactions. Life Sci 78 (2006) 2131-2145
39. Lin J.H., and Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 42 (2003) 59-98
40. Callaghan R., Crowley E., Potter S., and Kerr I.D. P-glycoprotein: so many ways to turn it on. J Clin Pharmacol 48 (2008) 365-378
41. Ottaiano A., De Chiara A., Fazioli F., Talamanca A.A., Mori S., Botti G., et al. Biological prognostic factors in adult soft tissue sarcomas. Anticancer Res 25 (2005) 4519-4526
42. Jamroziak K., and Robak T. Pharmacogenomics of MDR1/ABCB1 gene: the influence on risk and clinical outcome of haematological malignancies. Hematology 9 (2004) 91-105
43. Tan B., Piwnica-Worms D., and Ratner L. Multidrug resistance transporters and modulation. Curr Opinion Oncol 12 (2000) 450-458
44. Ford J.M., Yang J.M., and Hait W.N. P-glycoprotein-mediated multidrug resistance: experimental and clinical strategies for its reversal. Cancer Treat Res 87 (1996) 3-38
45. Schinkel A.H., Mayer U., Wagenaar E., Mol C.A., van Deemter L., Smit J.J., et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 94 (1997) 4028-4033
46. Modok S., Mellor H.R., and Callaghan R. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr Opin Pharmacol 6 (2006) 350-354
47. Atadja P., Watanabe T., Xu H., and Cohen D. PSC-833, a frontier in modulation of P-glycoprotein mediated multidrug resistance. Cancer Metastasis Rev 17 (1998) 163-168
48. Greenberg P.L., Lee S.J., Advani R., Tallman M.S., Sikic B.I., Letendre L., et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol 22 (2004) 1078-1086
49. Advani R., Saba H.I., Tallman M.S., Rowe J.M., Wiernik P.H., Ramek J., et al. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood 93 (1999) 787-795
50. Wang R.B., Kuo C.L., Lien L.L., and Lien E.J. Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors. J Clin Pharm Ther 28 (2003) 203-228